Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones.
Ianevski A, Nader K, Driva K, Senkowski W, Bulanova D, Moyano-Galceran L, Ruokoranta T, Kuusanmäki H, Ikonen N, Sergeev P, Vähä-Koskela M, Giri AK, Vähärautio A, Kontro M, Porkka K, Pitkänen E, Heckman CA, Wennerberg K, Aittokallio T. Ianevski A, et al. Among authors: aittokallio t. Nat Commun. 2024 Oct 3;15(1):8579. doi: 10.1038/s41467-024-52980-5. Nat Commun. 2024. PMID: 39362905 Free PMC article.
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations.
Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T. Ianevski A, et al. Among authors: aittokallio t. Sci Adv. 2021 Feb 19;7(8):eabe4038. doi: 10.1126/sciadv.abe4038. Print 2021 Feb. Sci Adv. 2021. PMID: 33608276 Free PMC article.
Robust scoring of selective drug responses for patient-tailored therapy selection.
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T. Chen Y, et al. Among authors: aittokallio t. Nat Protoc. 2024 Jan;19(1):60-82. doi: 10.1038/s41596-023-00903-x. Epub 2023 Nov 23. Nat Protoc. 2024. PMID: 37996540 Review.
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Pemovska T, et al. Among authors: aittokallio t. Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20. Cancer Discov. 2013. PMID: 24056683
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O. Malani D, et al. Among authors: aittokallio t. Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11. Leukemia. 2017. PMID: 27833094 Free PMC article.
257 results